This year the National Institutes of Health is set to request its biggest budget yet for 2024, on the heels of its previous biggest budget in 2023. As the COVID-19 pandemic fades from view, labs will switch back to other avenues of research, often funded by the NIH. This higher level of funding, coming on the heels of the COVID-19 pandemic and associated biotech boom, could be big money for the people who make and sell equipment. As the saying goes, in a gold rush, the best job is a shovel salesman. University labs are the biggest beneficiaries of NIH funding. These groups tend to be smaller than corporate labs and have less time to compare every product line when purchasing. Therefore, they tend to purchase from large, trusted companies above all else. I will be discussing three companies that are well-known by researchers, making them some of the most likely beneficiaries of the NIH’s largesse. Ultimately, these three companies have positioned themselves well as some of the most promising biotech stocks to buy in 2023.

Major players in the proteomics market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Danaher Corporation, Merck KGaA, Waters Corporation, Perkinelmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, GE Healthcare, Caprion Biosciences, Luminex Corporation, LI-COR Inc. Major players in the proteomics market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Danaher Corporation, Merck KGaA, Waters Corporation, Perkinelmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, GE Healthcare, Caprion Biosciences, Luminex Corporation, LI-COR Inc.

WILMINGTON, DE / ACCESSWIRE / February 22, 2023 / Transparency Market Research Inc. - The rise in demand for laboratory rapid tests at hospitals are generating sizable lucrative opportunities for players in Rapid Test Market , mainly owing to their affordability. Hospitals thus present the fastest growing market for rapid tests, propelled by enormous application of the tests for a wide range of diseases. Of the various technologies, the study found that immunoassays accounted for the largest revenue generator in the rapid test market in 2021. The global market is forecast to expand at a CAGR of 8.0% during 2022-2031. The demand for products in the rapid test market is spurred by an explosive rise in demand for COVID-19 testing, including at-home tests. Of note, players are leaning toward integrating cutting-edge technologies for enabling accurate and rapid tests for COVID-19. A case in point is the growing popularity of the rapid antigen test (RAT), found in recent developments in the rapid test market Industry players in the rapid test market are keen on expanding the reach of services through hospital networks in various geographies.

Related Stocks: IWM , VOO , QQQ , ROST , BIO ,

Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ETCompany ParticipantsEdward Chung - Vice President, Investor RelationsIlan Daskal -…

HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO) on Thursday reported fourth-quarter net income of $827.7…

Bio-Rad Labs press release (BIO): Q4 Non-GAAP EPS of $3.31.Revenue of $730.3M (-0.3% Y/Y).For FY 2023, co anticipates non-GAAP, currency-neutral revenue growth of approximately 6.0%…

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 percent compared to $732.8 million reported for the fourth quarter of 2021. COVID-related revenue was approximately $13 million in the fourth quarter of 2022 versus approximat

Bio-Rad Laboratories (NYSE: BIO ) is set to give its latest quarterly earnings report on Thursday, 2023-02-16. Here''s what investors need to know before the announcement. Analysts estimate that Bio-Rad Laboratories will report an earnings per share (EPS) of $3.45. Bio-Rad Laboratories bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com

Related Stocks: Y , BIO , EXC , ACGL , DVN ,

Major players in the hematology diagnostics devices and equipment market are Abbott Diagnostics, Beckman Coulter, Bio-Rad Laboratories, Drucker Diagnostics, Horiba Ltd, Instrumentation Laboratory Inc, Siemens Healthcare, Shenzhen Mindray Bio-Medical Electronics Co Ltd, F. Major players in the hematology diagnostics devices and equipment market are Abbott Diagnostics, Beckman Coulter, Bio-Rad Laboratories, Drucker Diagnostics, Horiba Ltd, Instrumentation Laboratory Inc, Siemens Healthcare, Shenzhen Mindray Bio-Medical Electronics Co Ltd, F.

Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc., Abbott Laboratories, Immucor Inc, Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc. Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc., Abbott Laboratories, Immucor Inc, Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc.

Major players in the food and beverages testing kits market are SGS, Eurofins, Intertek, Mérieux, Bio-Rad Laboratories Inc., Ecolab Inc, Bureau Veritas S.A., ALS Limited, AsureQuality, and FoodChain ID. Major players in the food and beverages testing kits market are SGS, Eurofins, Intertek, Mérieux, Bio-Rad Laboratories Inc., Ecolab Inc, Bureau Veritas S.A., ALS Limited, AsureQuality, and FoodChain ID.

In December 2021, IDEXX Laboratories, Inc. (US) acquired Reference Laboratories (Finland) to expanded the company''s international reference laboratory presence. Northbrook, IL 60062 -- ( SBWIRE ) -- 02/08/2023 -- Legionella Testing Market is projected to grow from USD 296 million in 2022 to USD 439 million by 2027, at a CAGR of 8.2% from 2022 to 2027, according to a new report by MarketsandMarkets™. ,as businesses around the world look to protect their employees, customers and other visitors. Legionella testing is becoming an increasingly important part of many businesses'' safety and health protocols. As awareness of Legionella bacteria and the threat it poses to the health of building occupants grows, so does the demand for testing to ensure that Legionella levels in water systems remain low. In this blog post, we''ll take a look at the current state of the Legionella testing market, the key drivers of its growth and the challenges it faces. We''ll also look at the different types of Legionella tests available, the benefits they offer, and the importance of conducting regular testing.

New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered into a strategic partnership with leading life science research and clinical diagnostics products company Bio-Rad Laboratories,